Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators; John W Eikelboom; Graeme J Hankey; Jim Thom; Deepak L Bhatt; P Gabriel Steg; Gilles Montalescot; S Claiborne Johnston; Steven R Steinhubl; Koon-Hou Mak; J Donald Easton; Christian Hamm; Tingfei Hu; Keith A A Fox; Eric J Topol

doi:10.1161/CIRCULATIONAHA.108.768283

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators, John W Eikelboom, Graeme J Hankey, Jim Thom, Deepak L Bhatt, P Gabriel Steg, Gilles Montalescot, S Claiborne Johnston, Steven R Steinhubl, Koon-Hou Mak, J Donald Easton, Christian Hamm, Tingfei Hu, Keith A A Fox, Eric J Topol

Research output: Contribution to journal › Article › peer-review

Abstract

Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydro thromboxane B(2) concentrations, has been associated with an increased risk of cardiovascular events. We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B(2) concentrations that could thereby reduce cardiovascular risk.

Original language	English
Pages (from-to)	1705-12
Number of pages	8
Journal	Circulation
Volume	118
Issue number	17
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.108.768283
Publication status	Published - Oct 2008

Access to Document

10.1161/CIRCULATIONAHA.108.768283

Cite this

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators, Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K.-H., Easton, J. D., Hamm, C., Hu, T., Fox, K. A. A., & Topol, E. J. (2008). Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation, 118(17), 1705-12. https://doi.org/10.1161/CIRCULATIONAHA.108.768283

@article{f49fc34cad544e41b7878fe54a46c27a,

title = "Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk",

abstract = "Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydro thromboxane B(2) concentrations, has been associated with an increased risk of cardiovascular events. We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B(2) concentrations that could thereby reduce cardiovascular risk.",

author = "{Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators} and Eikelboom, {John W} and Hankey, {Graeme J} and Jim Thom and Bhatt, {Deepak L} and Steg, {P Gabriel} and Gilles Montalescot and Johnston, {S Claiborne} and Steinhubl, {Steven R} and Koon-Hou Mak and Easton, {J Donald} and Christian Hamm and Tingfei Hu and Fox, {Keith A A} and Topol, {Eric J}",

year = "2008",

month = oct,

doi = "10.1161/CIRCULATIONAHA.108.768283",

language = "English",

volume = "118",

pages = "1705--12",

journal = "Circulation",

issn = "0009-7322",

publisher = "AMER HEART ASSOC",

number = "17",

}

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators, Eikelboom, JW, Hankey, GJ, Thom, J, Bhatt, DL, Steg, PG, Montalescot, G, Johnston, SC, Steinhubl, SR, Mak, K-H, Easton, JD, Hamm, C, Hu, T, Fox, KAA & Topol, EJ 2008, 'Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk', Circulation, vol. 118, no. 17, pp. 1705-12. https://doi.org/10.1161/CIRCULATIONAHA.108.768283

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. / Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators; Eikelboom, John W; Hankey, Graeme J et al.
In: Circulation, Vol. 118, No. 17, 10.2008, p. 1705-12.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid

T2 - determinants and effect on cardiovascular risk

AU - Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators

AU - Eikelboom, John W

AU - Hankey, Graeme J

AU - Thom, Jim

AU - Bhatt, Deepak L

AU - Steg, P Gabriel

AU - Montalescot, Gilles

AU - Johnston, S Claiborne

AU - Steinhubl, Steven R

AU - Mak, Koon-Hou

AU - Easton, J Donald

AU - Hamm, Christian

AU - Hu, Tingfei

AU - Fox, Keith A A

AU - Topol, Eric J

PY - 2008/10

Y1 - 2008/10

N2 - Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydro thromboxane B(2) concentrations, has been associated with an increased risk of cardiovascular events. We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B(2) concentrations that could thereby reduce cardiovascular risk.

AB - Incomplete inhibition of platelet thromboxane generation, as measured by elevated urinary 11-dehydro thromboxane B(2) concentrations, has been associated with an increased risk of cardiovascular events. We aimed to determine the external validity of this association in aspirin-treated patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial and to determine whether there are any modifiable factors or interventions that lower urinary 11-dehydro thromboxane B(2) concentrations that could thereby reduce cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=55449132867&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.108.768283

DO - 10.1161/CIRCULATIONAHA.108.768283

M3 - Article

C2 - 18838564

SN - 0009-7322

VL - 118

SP - 1705

EP - 1712

JO - Circulation

JF - Circulation

IS - 17

ER -

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators, Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008 Oct;118(17):1705-12. doi: 10.1161/CIRCULATIONAHA.108.768283

Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk

Abstract

Access to Document

Other files and links

Fingerprint

Cite this